Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 May;87(5):532-4.
doi: 10.1002/ajh.23138. Epub 2012 Mar 3.

A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia

Affiliations
Case Reports

A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia

Michele P Lambert et al. Am J Hematol. 2012 May.

Abstract

Essential thrombocythemia (ET) is a rare type of myeloproliferative neoplasm characterized by clonal expansion of the megakaryocyte and platelet lineage. Here, we describe a novel mutation (Y252H) in the thrombopoietin (TPO) receptor, or MPL, in a JAK2 mutation-negative ET patient. The bone marrow examination revealed increased numbers of dysmorphic megakaryocytes with focal clustering. The x-inactivation pattern suggested clonal expansion of hematopoietic cells in the bone marrow. Furthermore, we found that the patient's bone marrow cells were hypersensitive to TPO in generating megakaryocyte colonies in vitro. More importantly, we demonstrated that this MPL Y252H mutant confers increased TPO/MPL-mediated cell growth and increased cell survival upon cytokine withdrawal in BaF3 cells, indicating it is a disease-driving mutation and may contribute to the development of ET in vivo. In summary, this is the first report describing a mutation in the extracellular domain of MPL underlying ET.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant conflict of interest.

Figures

Figure 1
Figure 1. The MPL Y252H mutation enhances TPO-mediated megakaryocyte colony formation as well as TPO-dependent cell growth
(A) Hematoxylin & Eosin staining from the bone marrow biopsy of the patient is shown. Arrow indicates abnormal megakaryocyte clusters, while arrowheads indicate dysmorphic megakaryocytes with atypical nuclear chromatin patterns varying from widely dispersed nuclei to markedly hyperchromatic. (B) Bone marrow cells from the patient and a healthy control were subjected to Megacult colony assay with varying concentrations of TPO according to manufacturer’s instructions. Megakaryocyte colonies were enumerated from 4 replicates per group. p<0.001 by ANOVA. (C) Ba/F3 cells stably expressing vector alone, WT or the Y252H mutant MPL were generated by retroviral infection and live cell numbers were determined using an MTT assay. Results were normalized to the growth in IL-3. (D) Ba/F3 cells expressing vector alone, WT or Y252H MPL, were washed extensively and cultured in the absence of cytokines. Cell numbers were determined by Trypan blue staining using a hemacytometer. For all graphs in panels B-D, *: p<0.05; **: p<0.005.

Similar articles

Cited by

References

    1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22. - PubMed
    1. Drachman JG, Kaushansky K. Structure and function of the cytokine receptor superfamily. Curr Opin Hematol. 1995;2:22–28. - PubMed
    1. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol. 1996;12:91–128. - PubMed
    1. Beer PA. The pathogenesis of essential thrombocythemia. Curr Opin Hematol. 2011;18:323–329. - PubMed
    1. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270. - PMC - PubMed

Publication types

MeSH terms